STEM -- StemCells, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : STEM -- StemCells, Inc.

STEM 16.67

+0.9%

Nov 14 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: cl who wrote (33)	3/27/1997 7:29:00 PM
From: Miljenko Zuanic	of 805

CL, CTII and GNE are already in partnership. Also GNE and ALKS are on project: passing BBB with RMP-7. For now AMGN is focusing on Medtronic intrathecal pump (CNTF, GDNF and BDNF brain factors/proteins). After AMGN licensed form Progenitor "Receptors for leptin", they will need more elegant delivery method for this target. Recently research from MTI reported (they also received patent) that they develop special membrane (also implant) for sustain release of small molecules in brain. This can be AMGN consideration. AMGN can license CTII technology, but for now I do not think they will. Although, news are positive, writer mentioned only preclinical study-Nature article. There are no data that implant-CNTF is in phase II for ALS, and similar device for natural analgesics (Astra) is in phase II for chronic pain. As you know, same indication as for NXCO SNX-111. Somebody will do research, and by time market will react properly. mz

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next